Kaya17

About Us

Kaya17, a privately held business funded by investors, was established in 2015 with the primary objective of reducing the time between testing, diagnosis and treatment. Also, based on personal experience, it was critical to us to be able to test when and where needed rather than in specialized facilities.

Building upon our success in identifying food pathogens in produce (fruits and vegetables), we have updated the design of the various components to be able to identify bacteria, virus, pollen and other protein-based pathogens in small specimen samples with very high sensitivity.

Currently, we are focusing on adapting our technology for the quick and timely diagnosis of the SARS-CoV-2 virus, which has caused the largest pandemic in recent history.

Management Team

CEO

Sulatha Dwarakanath, PhD

CEO / Co-Founder

Su has a PhD in Molecular Biology from New York University

She has over 20 years of experience in Product Innovation, Development and Strategy at Roche Diagnostics, Thermo Fisher Scientific, and Bayer Diagnostics.

She was the Founder and Chief Scientific Officer of Nano Science Diagnostics, a Point of Care focused company.

Srinagesh Satyanarayana, PhD

Co-Founder

Sri has a PhD in Electrical Engineering from Columbia University

He has more than 25 years of experience in Analog chip design electronic systems, medical devices, and Artificial Intelligence based systems.

He was the Founder and CEO of Free Electron Technology, a 10 Gbps Communications Chip company.

Camille Troup, PhD

Chief Scientific Officer

Camille received her PhD in Molecular Biology from University of California at San Francisco

She has over 25 years of experience developing and commercializing biomolecular assays and platforms.

Anup Madan

Chief Operations Officer

Anup brings more than 20 years of experience in delivering innovative solutions to support multiple aspects of clinical trials.

Rajan Pillai

VP of Business Development

He co-founded Duramed Pharmaceuticals which went public, Trinity Laboratories, which was acquired, and a mail order prescription drug company, Medi Rx America, which went public. He has worked as Managing Director at Peregrine Capital Ltd. in Hong Kong for four years during 1993-1997. During his years as a practicing attorney in New York, he has represented the Governments of Indonesia and Sweden in certain commercial matters, and has handled several IPOs of successful early stage enterprises

Advisory Panel

Steve Verbinski, MD

Co-Director and Hospitalist at Rose Hospital, Hayward, California

Prominent member and Physician Advisor to the COVID Response Task Force / Command Center St. Rose Hospital

Mitchell Levinson

Medical Device Developer & Entrepreneur

Experienced medical device developer and entrepreneur with over 30 years in the industry.

In 2010, Mr. Levinson co-founded Cerebrotech Medical Systems, Inc..

Previously CEO of Zeltiq Aesthetics, Inc. (Coolsculpting, ZLTQ) and VP of Thermage, Inc. (later renamed Solta Medical, SLTA). Levinson also sits on the Board of Directors of Pulse Biosciences (PLSE)  and ConnectWell.​

Allyson Tevrizian, MD

Clinical Practice, Allergy and Asthma Medical Group of Bay Area, Pleasanton

  

George H. Caughey, MD

Chief of Pulmonary and Critical Care Medicine, Julius and Lilian Nadel Endowed Chair, UCSF; Professor Emeritus, Medicine, UCSF

  

Nancy B. Mozelsio, MD

Clinical Practice, Allergy & Asthma Medical Group of Bay Area, Pleasanton & Walnut Creek

  

Yolanda Fintschenko

FounderTraction; Digital Marketing for Tech and Biotech